Rosuvastatin treatment was associated with a significant reduction in CIAKI compared with the controls ( @ % vs. @ % , P = @ ) in the overall cohort and in patients with MCV ( @ % vs. @ % , P = @ ) , whereas no benefit was observed in patients with HCV ( @ % vs. @ % , P = @ ) .